tailieunhanh - Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis

Efficacy trials showed that glucagon-like peptide–1 receptor (GLP1R) agonists reduced metabolic risk factors in addition to glucose lowering, but the cardiovascular and microvascular efficacy of this drug class remains to be determined. | Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis

TỪ KHÓA LIÊN QUAN